Clinical Trial Detail

NCT ID NCT02330562
Title Study of Marizomib With Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Triphase Research and Development I Corporation
Indications

malignant glioma

Therapies

Bevacizumab + Marizomib

Age Groups: adult

No variant requirements are available.